U.S. markets close in 1 hour 45 minutes

Cerecor Inc. (CERC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.5300-0.0300 (-0.84%)
As of 2:15PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.5600
Open3.5200
Bid3.5000 x 1000
Ask3.5500 x 1000
Day's Range3.5100 - 3.6400
52 Week Range1.9800 - 4.5000
Volume415,508
Avg. Volume1,857,417
Market Cap341.453M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 10 Best Biotech Penny Stocks to Buy Now
    Insider Monkey

    10 Best Biotech Penny Stocks to Buy Now

    In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Biotech Penny Stocks to Buy Now. The scintillating pace of technological advancement in the world over the past few decades has transformed the fortunes […]

  • How Many Cerecor Inc. (NASDAQ:CERC) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Cerecor Inc. (NASDAQ:CERC) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients
    Benzinga

    Cerecor Shares Gain After FDA Fast Track Review Tag For CERC-002 In Hospitalized COVID-19 Patients

    The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting LIGHT (tumor necrosis factor superfamily member 14, TNFSF14). Fast Track designation provides an opportunity for more frequent interactions with the FDA review team throughout the development program. Under Fast Track designation, a Biologic License Application (BLA) for CERC-002 is eligible for both rolling submission and priority review.1 In March, the company announced final efficacy data from the Phase 2 trial evaluating CERC-002 for COVID-19 associated pneumonia and acute respiratory distress syndrome (ARDS). At both the 28-day and the 60-day final timepoints, an approximately 50% trend in mortality reduction (22.5% vs. 10.8%) was observed. Price Action: CERC shares are up 15% at $2.92 during the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaPandemic Hits Perrigo Q1 Top And BottomlineBiogen, Capsigen Ink .3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.